Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.

Melissa L Johnson,James Strauss,Manish R Patel,Edward B Garon,Keith D Eaton,Tavette Neskorik, Josée Morin,Richard Chao,Balazs Halmos

Clinical Lung Cancer（2023）

引用 1|浏览13

暂无评分

摘要

Mocetinostat 70 mg TIW plus durvalumab at the standard dose was generally well tolerated. Clinical activity was observed in patients with NSCLC unresponsive to prior anti-PD-(L)1 therapy.

查看译文

关键词

Checkpoint inhibitor,HDAC,Histone deacetylase inhibitor,PDL1,Programmed death-ligand 1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要